Selenite (Sodium) / PARP Cancer Research Results

SSE, Selenite (Sodium): Click to Expand ⟱
Features:
Sodium Selenite - is inorganic selenium in the selenite oxidation state (Se⁴⁺)
Sodium selenite is produced industrially from selenium metal, which itself is obtained as a by-product of copper refining.
Mechanistic distinction from Selenium:
-Selenite reacts with GSH → GS–Se–SG intermediates
-Generates superoxide, H₂O₂
-Exploits cancer cells’ elevated basal oxidative stress
-Normal cells neutralize it more effectively (higher redox reserve)

Both the uptake and processing of selenium has recently shown to be upregulated in subsets of cancer cells
 due to their increased expression of xCT transporter
The more a tumor depends on xCT, the more toxic selenite becomes. High xCT Also Increases SSE Toxicity. High xCT increases intracellular thiols, which increases SSE chemical trapping, redox cycling, and cytotoxic impact.

Sodium selenite might protect against toxicity of AgNPs. also here


SSE and cancer
Rank Pathway / Target Axis Direction Primary Effect Notes / Cancer Relevance Ref
1 Redox cycling with thiols (superoxide generation) ↑ O2•− / ↑ ROS Acute oxidative stress Defines sodium selenite anticancer mechanism in many models: early superoxide rise precedes mitochondrial apoptotic events (ref)
2 Glutathione buffering (GSH pool) ↓ GSH Loss of redox buffering Work in hepatoma models demonstrates GSH’s key role in selenite-driven oxidative stress and apoptosis (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Mitochondrial dysfunction Sequential mechanism shown: superoxide rise → mitochondrial depolarization (ref)
4 Intrinsic apoptosis (cytochrome c → Caspase-9/3) ↑ cytochrome c release / ↑ Caspase-9/3 Programmed cell death Same sequential model shows cytochrome c release followed by caspase-9 and caspase-3 activation (ref)
5 ER stress / UPR (PERK → eIF2α → ATF4) ↑ PERK/eIF2α/ATF4 Proteotoxic stress signaling ER-stress module is shown as a core driver in selenite-induced autophagy→apoptosis progression (ref)
6 Stress MAPK (p38) as switch control ↑ p38 activation Signal switching (autophagy → apoptosis) Mechanistic evidence for p38 participating in the selenite-driven transition toward apoptosis (ref)
7 p53 activation (stress response) ↑ p53 phosphorylation (Ser15) Facilitates apoptosis programs NB4 leukemia model: selenite induces p53 Ser15 phosphorylation via p38/ERK in the autophagy–apoptosis switch context (ref)
8 DNA damage response (ATM-dependent signaling) ↑ ATM-dependent DDR Checkpoint activation & death signaling Selenium compounds (including selenite contexts) activate ATM-dependent DNA damage response signaling in colorectal cancer models (ref)
9 PI3K–AKT axis linked to autophagy/apoptosis balance ↓ PI3K/Akt (functional axis) / ↓ protective autophagy Apoptosis sensitization NB4 leukemia: sodium selenite increases apoptosis by autophagy inhibition through PI3K/Akt (ref)
10 NF-κB signaling ↓ NF-κB Reduced anti-apoptotic transcription Mechanistic study: sodium selenite induces ROS-mediated inhibition of NF-κB with downstream shift toward apoptosis (ref)
11 Angiogenesis signaling (VEGF) ↓ VEGF expression Reduced vascular support signals Prostate cancer PC3 model: sodium selenite inhibits expression of VEGF (and related inflammatory/pro-growth factors) in the tested context (ref)
12 Ferroptosis (iron-dependent oxidative death) ↑ ferroptosis Non-apoptotic oxidative death modality Paper explicitly reports sodium selenite as an inducer of ferroptosis across multiple human cancer cell types (ref)

Table to compare Sodium Selenite to SeNPs
-Sodium selenite → chemical oxidant (thiol attack → ROS shock).
-SeNPs → engineered redox stressor (signaling-level control, broader window).
-Selenomethionine / Se-yeast → redox buffer & selenium storage form (often protective to cancer cells, especially when oxidative stress is a therapeutic goal).
Dimension Sodium Selenite (Na2SeO3) Selenium Nanoparticles (SeNPs) Selenomethionine / Se-Yeast
Primary mechanistic class Direct redox-disrupting agent Controlled redox modulator / signaling perturbator Nutritional selenium reservoir / selenoprotein precursor
Initial molecular interaction Rapid reaction with cellular thiols (GSH, Trx, protein –SH) Cellular uptake → gradual selenium release or surface redox effects Nonspecific incorporation into proteins in place of methionine
ROS generation ↑↑ acute, non-buffered ROS burst ↑ mild–moderate, sustained ROS ↓ or ↔ (antioxidant bias)
Glutathione (GSH) system ↓↓ GSH depletion ↔ or mild ↓ (context-dependent) ↑ GSH recycling via GPX support
Redox selectivity (cancer vs normal) Limited; toxicity threshold close to efficacy Improved tumor selectivity window Poor for cancer killing; favors normal-cell protection
Mitochondrial integrity (ΔΨm) ↓↓ rapid depolarization ↓ gradual, dose-dependent disruption ↔ or ↑ mitochondrial protection
Dominant cell-death pathways Intrinsic apoptosis ± necrosis (high dose) Apoptosis ± ferroptosis ± autophagy-related death None (cytoprotective)
ER stress / UPR (PERK–CHOP) ↑ strong, early activation ↑ moderate, delayed activation ↓ ER stress via antioxidant capacity
DNA damage response ↑ oxidative DNA lesions (ATM/ATR) ↑ low–moderate, secondary to ROS ↓ DNA damage; improved repair environment
PI3K–AKT survival signaling ↓ secondary to oxidative collapse ↓ reported in multiple tumor models ↔ or ↑ survival signaling
NF-κB / inflammatory signaling ↓ via redox inhibition ↓ selectively; anti-inflammatory bias ↓ chronic inflammation (protective)
Ferroptosis involvement Minor / indirect ↑ lipid peroxidation; GPX4 modulation ↓↓ ferroptosis risk (GPX4 support)
Autophagy ↑ early (protective) → collapse ↑ contributory to tumor suppression ↔ homeostatic maintenance
Angiogenesis (VEGF) ↓ at cytotoxic doses ↓ at lower, tolerated doses ↔ or mild ↓ (indirect)
Immune compatibility Poor at anticancer doses Moderate–good; often immune-supportive High; supports immune competence
Pharmacologic control Poor (steep dose–toxicity curve) High (size, coating, release tunable) Low (slow turnover, storage form)
Normal tissue tolerance Low Moderate–high High
Overall cancer relevance Potent but hazardous cytotoxic agent Balanced anticancer redox modulator Generally counterproductive for direct cancer killing
Overall therapeutic profile Potent but narrow safety margin Lower acute potency, broader usable window


PARP, poly ADP-ribose polymerase (PARP) cleavage: Click to Expand ⟱
Source:
Type:
Poly (ADP-ribose) polymerase (PARP) cleavage is a hallmark of caspase activation. PARP (Poly (ADP-ribose) polymerase) is a family of proteins involved in a variety of cellular processes, including DNA repair, genomic stability, and programmed cell death. PARP enzymes play a crucial role in repairing single-strand breaks in DNA.
PARP has gained significant attention, particularly in the treatment of certain types of tumors, such as those with BRCA1 or BRCA2 mutations. These mutations impair the cell's ability to repair double-strand breaks in DNA through homologous recombination. Cancer cells with these mutations can become reliant on PARP for survival, making them particularly sensitive to PARP inhibitors.
PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been developed as targeted therapies for cancers associated with BRCA mutations.

PARP Family:
The poly (ADP-ribose) polymerases (PARPs) are a family of enzymes involved in a number of cellular processes, including DNA repair, genomic stability, and programmed cell death.
PARP1 is the predominant family member responsible for detecting DNA strand breaks and initiating repair processes, especially through base excision repair (BER).

PARP1 Overexpression:
In several cancer types—including breast, ovarian, prostate, and lung cancers—elevated PARP1 expression and/or activity has been reported.
High PARP1 expression in certain cancers has been associated with aggressive tumor behavior and resistance to therapies (especially those that induce DNA damage).
Increased PARP1 activity may correlate with poorer overall survival in tumors that rely on DNA repair for survival.
Scientific Papers found: Click to Expand⟱
1002- SSE,  Osi,  Adag,    Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
- in-vitro, Lung, H1975 - in-vitro, Lung, H385
Apoptosis↑, Ferroptosis↑, DNMT1↓, TET1↑, TumCCA↑, cl‑PARP↑, cl‑Casp3↑, Cyt‑c↑, BIM↑, NOXA↑, Apoptosis↑, ROS↑, ER Stress↑, UPR↑,
4468- VitC,  SSE,    Selenium modulates cancer cell response to pharmacologic ascorbate
- in-vivo, GBM, U87MG - in-vitro, CRC, HCT116
eff↓, TumCD↑, ChemoSen↑, ROS⇅, DNAdam↑, PARP↑, NAD↓, Glycolysis↓, Fenton↑, lipid-P↑, eff↓, H2O2↑, other↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   Ferroptosis↑, 1,   H2O2↑, 1,   lipid-P↑, 1,   ROS↑, 1,   ROS⇅, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   NAD↓, 1,  

Cell Death ⓘ

Apoptosis↑, 2,   BIM↑, 1,   cl‑Casp3↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   NOXA↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,   UPR↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 1,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Migration ⓘ

TET1↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↓, 2,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PARP, poly ADP-ribose polymerase (PARP) cleavage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:148  Target#:239  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page